此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pediatric Immune Response to Infectious Shock (PedIRIS)

2018年11月9日 更新者:Hospices Civils de Lyon

Infectious shocks are associated with high mortality rates (20-40%). Anti-inflammatory strategies based on the postulate that mortality related to sepsis is mainly due to an overwhelming pro-inflammatory immune response have failed. Some patients surviving this initial phase can develop immune dysfunctions because the compensatory mechanisms become deleterious when they persist over time. The persistence of immunosuppression at day 3 or 5 is independently associated with more nosocomial infections and higher mortality rate. The clinical and laboratory evidence for sepsis induced immunosuppression have been recently reviewed by Hotchkiss et al. Apoptosis-induced depletion of immune effector and blood studies from septic patients showed decreased production of pro-inflammatory cytokines, decreased HLA-DR expression, increased percentage of regulatory T cells, and increased production of programmed cell death (PD)-1. Some small positive phase 2 trials of biomarker guided immune enhancing agents granulocyte-macrophage colony stimulating factor (GM-CSF) and interferon γ (IFN γ) have been reported.

There are insufficient data showing that such an immunosuppression exists in children. Only one study performed in children with organ dysfunctions admitted to pediatric intensive care unit (PICU), showed that 34% of them developed immunosuppression. This study was performed on a heterogeneous population and immunological analyses were limited. Therefore, there is a crucial need of studies on septic patients with matched controls to provide more evidence that the same paradigm exists in children. The collaboration of laboratories with a high level of experience in this domain, and a clinical unit with a high potential of recruitment of children with severe infectious shock should allow us to perform the first prospective study specifically done in children with infectious shock.

The main hypothesis is that children with severe infectious shock developed sepsis-induced immunosuppression as shown in adults. This will be assessed by the expression of HLA-DR on monocytes' surface. We make the hypothesis that children who become immunosuppressed are more prone to develop secondary nosocomial infectious and stayed longer in PICU and in hospital.

Children aged from 1 month to 17 years, admitted to PICU at HFME Lyon-Bron are eligible if they have the criteria for severe sepsis or septic shock, defined by the "Surviving Sepsis Campaign 2012" or those of Toxic Shock Syndrome (TSS) (definitions of CDC - Center for Disease Control). An information leaflet will be issued to parents and children / adolescents and they will be informed of their right to object to the search. Are provided as part of this research:

  • Immunological measures (mHLA -DR) in three stages: in the first 48 hours, between D3/5 and D7/9. The volume of collected blood will not exceed 2.4 ml / kg.
  • The collection of nosocomial infections and status at D30 A control group of patients hospitalized for surgery without sepsis or toxic shock criteria will be recruited in the same hospital by ICU investigators and matched for age. Similarly controls will be given oral and written information and they will have the opportunity to deny inclusion. They will have the same exams as the first group of patients.

研究概览

研究类型

介入性

注册 (实际的)

105

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Lyon、法国
        • Hospices Civils De Lyon

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1个月 至 17年 (孩子)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria Infectious shock group:

  • Children aged from 1 month to <18 years
  • Diagnosis of severe infectious shock at PICU or within the first 24 hours following PICU admission: severe sepsis or septic shock, defined by Surviving Sepsis Campaign 2012, or Toxic Shock Syndrome, defined by CDC criteria.

Inclusion Criteria Control group:

  • Healthy children aged matched to cases
  • Hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage)
  • Without any criteria of infection.

Exclusion Criteria (both groups):

  • Chronic inflammatory disease;
  • Immunodeficiency;
  • Long-term corticosteroids;
  • Ongoing immunosuppressive treatment;
  • Transplanted patients;
  • Tumors, hematological diseases;
  • No health insurance coverage;
  • Refusal to participate (from parents and/or patient) or inability to understand information.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Children with infectious shock
Children aged from 1 month to <18 years. In 3 stratified groups : <2 years, 2-8 years, and >8 years. About one third of the patients are expected in each age-group.
其他:Control group: healthy children
Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
proportion of patients with a mHLA-DR level <30%
大体时间:up to Day 9
mHLA-DR is measured by flow cytometry
up to Day 9
proportion of patients with a mHLA-DR level significantly lower than healthy children.
大体时间:in the pre-operative period
mHLA-DR is measured by flow cytometry
in the pre-operative period

次要结果测量

结果测量
措施说明
大体时间
total lymphocytes
大体时间:Day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
Day 1
total lymphocytes
大体时间:between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
total lymphocytes
大体时间:between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
levels of CD4+
大体时间:Day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
Day 1
levels of CD4+
大体时间:between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
levels of CD4+
大体时间:between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
levels of CD25+
大体时间:day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
day 1
levels of CD25+
大体时间:between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
levels of CD25+
大体时间:between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
levels of T lymphocytes (Treg)
大体时间:Day 1
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
Day 1
levels of T lymphocytes (Treg)
大体时间:between Day 3 and day 5
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 3 and day 5
levels of T lymphocytes (Treg)
大体时间:between Day 7 and day 9
From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies
between Day 7 and day 9
dosage of cytokines
大体时间:Day 1
Day 1
dosage of cytokines
大体时间:between Day 3 and day 5
between Day 3 and day 5
dosage of cytokines
大体时间:between Day 7 and day 9
between Day 7 and day 9
Number of nosocomial infections
大体时间:up to Day 30
up to Day 30
Type of nosocomial infections
大体时间:up to Day 30
bacteremia, ventilator-associated pneumonia, urinary tract infection, other sites.
up to Day 30
Mortality
大体时间:up to Day 30
up to Day 30
Length of vasoactive treatments
大体时间:up to Day 30
up to Day 30

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Etienne JAVOUHEY、Hospices Civils De Lyon

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年9月26日

初级完成 (实际的)

2018年8月4日

研究完成 (实际的)

2018年8月4日

研究注册日期

首次提交

2016年7月21日

首先提交符合 QC 标准的

2016年7月25日

首次发布 (估计)

2016年7月28日

研究记录更新

最后更新发布 (实际的)

2018年11月14日

上次提交的符合 QC 标准的更新

2018年11月9日

最后验证

2018年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 69HCL16_0478

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

血液样本的临床试验

3
订阅